卡瑞利珠单抗联合紫杉醇+顺铂化疗方案对食管癌患者T淋巴细胞亚群及肿瘤标志物的影响  

Effects of Camrelizumab Combined with Paclitaxel+Cisplatin Chemotherapy on T Lymphocyte Subsets and Tumor Markers in Patients with Oesophageal Cancer

作　　者：贠春燕 YUN Chun-yan(Department of Medical Oncology,the Second Affiliated Hospital of Henan University of Science and Technology,Luoyang 471000,China)

机构地区：[1]河南科技大学第二附属医院肿瘤内科,洛阳471000

出　　处：《中国合理用药探索》2025年第3期23-28,共6页Chinese Journal of Rational Drug Use

摘　　要：目的:探讨卡瑞利珠单抗联合紫杉醇+顺铂(TP)化疗方案治疗食管癌患者的临床效果。方法:选取2019年6月~2022年6月期间某院收治的72例食管癌患者作为研究对象,采用随机数字表法分为对照组和观察组,每组36例。对照组患者给予TP化疗方案治疗,观察组患者在对照组治疗基础上给予注射用卡瑞利珠单抗治疗,两组均持续治疗4个疗程。比较两组肿瘤标志物[鳞状细胞癌抗原(SCCA)、癌胚抗原(CEA)]、T淋巴细胞亚群水平(CD4^(+)、CD8^(+)、CD4^(+)/CD8^(+))、生活质量[卡诺夫斯凯计分(KPS)]、临床疗效、不良反应发生情况以及治疗后随访12个月的生存情况。结果:治疗后,两组患者血清SCCA、CEA水平均降低(P<0.05),且观察组低于对照组(P<0.05);观察组患者CD8^(+)水平低于对照组(P<0.05),CD4^(+)、CD4^(+)/CD8^(+)水平高于对照组(P<0.05);两组患者KPS评分均升高(P<0.05),且观察组高于对照组(P<0.05);观察组患者治疗缓解率(52.78%)高于对照组(25.00%,P<0.05)。两组患者不良反应总发生率比较无统计学差异(P>0.05)。观察组患者总生存率(72.22%)高于对照组(41.67%,χ^(2)=6.269,P=0.012)。结论:卡瑞利珠单抗联合TP化疗方案治疗可提高食管癌患者的临床疗效,改善T淋巴细胞亚群水平及生活质量,降低肿瘤标志物水平,延长患者生存时间,且不会增加不良反应的发生风险。Objective:To investigate the clinical efficacy of camrelizumab combined with paclitaxel^(+)cisplatin(TP)chemotherapy in the treatment of oesophageal cancer.Methods:A total of 72 patients with oesophageal cancer treated in a hospital from June 2019 to June 2022 were selected and assigned to the control group and the observation group by random number table method,with 36 patients in each group.The control group was treated with TP chemotherapy,and the observation group was treated with camrelizumab for injection in addition to the treatment given in the control group.Both groups were treated for 4 courses.The levels of tumor markers[squamous cell carcinoma antigen(SCCA),carcinoembryonic antigen(CEA)],T lymphocyte subsets(CD4^(+),CD8^(+),CD4^(+)/CD8^(+)),quality of life[Karnofsky performance score(KPS)],clinical efficacy,adverse reactions and 12-month survival after treatment were compared between the two groups.Results:After treatment,the levels of serum SCCA and CEA were decreased in both groups(P<0.05),with the observation group showing lower levels than the control group(P<0.05).CD8^(+)in the observation group was lower than that in the control group(P<0.05),while CD4^(+)and CD4^(+)/CD8^(+)were higher than those in the control group(P<0.05).The KPS score was increased in both groups(P<0.05),with the observation group showing higher scores than the control group(P<0.05).The response rate in the observation group(52.78%)was higher than that in the control group(25.00%,P<0.05).No statistically significant difference was observed in the incidence of adverse reactions between the two groups(P>0.05).The overall survival rate in the observation group(72.22%)was higher than that in the control group(41.67%,χ^(2)=6.269,P=0.012).Conclusion:Camrelizumab combined with TP chemotherapy can improve the response rate in patients with oesophageal cancer,improving T lymphocyte subset levels and quality of life,reducing the tumor marker levels,prolonging patient survival,without increasing the incidence of adverse reactions.

关 键 词：食管癌 卡瑞利珠单抗 紫杉醇 顺铂 T淋巴细胞亚群 肿瘤标志物 

分 类 号：R735.1[医药卫生—肿瘤]